Amgen's RANKL-Targeting Antibody, Xgeva (Denosumab), Receives Definitive EMA Marketing Authorization
Regulatory Approval for Amgen's Leading Product, Xgeva
The European Medicines Agency (EMA) has finalized the marketing authorization for Xgeva (denosumab), Amgen's (AMGN) leading treatment for bone diseases, within Europe. Xgeva is a human monoclonal antibody that targets RANKL (Receptor Activator of Nuclear Factor-κB Ligand), a protein essential for the formation and activation of osteoclasts, the cells responsible for bone destruction. This approval is significant as it ensures treatment options for patients with bone metastases from solid tumors, multiple myeloma, and those with unresectable giant cell tumor of bone (GCTB), while also preventing skeletal-related events (SREs). Based on robust efficacy and safety data demonstrated in Phase 3 trials, Xgeva has successfully passed the EMA's rigorous review process, eliminating regulatory uncertainties.
Commercial Value of Approximately $2 Billion in Global Sales
Xgeva is one of Amgen's key revenue drivers, generating approximately $2.08 billion (USD) in global sales in 2024 and approximately $2.23 billion (USD) in 2025, making it a blockbuster drug. This official EMA approval and marketing authorization will solidify Amgen's strong revenue base within the European Union (EU) market, which has a population of approximately 500 million. With its proven commercial value and strong brand recognition, Xgeva is poised to become an essential treatment option for bone disease patients in Europe. The approval data will also serve as a strong negotiating tool in individual price negotiations with European member state health authorities and the process of listing on national health insurance programs.
Clinical Superiority and Differentiation Compared to Competing Drugs
In the SRE treatment market, Xgeva's strongest competitors are existing bisphosphonate-based therapies, such as Zometa (zoledronic acid) from Novartis. In a large-scale, head-to-head Phase 3 clinical trial, Xgeva demonstrated superior efficacy in significantly delaying the time to first SRE compared to Zometa. Unlike bisphosphonates, which are administered intravenously and carry a risk of renal toxicity, Xgeva is administered via subcutaneous injection, offering convenient administration and eliminating the need for dose adjustments based on renal function. This unique clinical advantage has made Xgeva highly preferred by physicians and patients in clinical practice.
Facing Biosimilar Competition and Portfolio Diversification
With the expiration of its original patent, biosimilars containing denosumab, such as Wyost from Sandoz, are now being launched, intensifying market competition. Through this EMA approval, Amgen is reconfirming the regulatory status of its Xgeva originator product and plans to leverage its accumulated long-term clinical data to defend against biosimilar competition. Although the entry of biosimilars poses risks of short-term price pressure and market share decline, Amgen is striving to maintain its market dominance by leveraging the clinical credibility and abundant real-world data of its originator product. From an investor perspective, this is a critical period to closely monitor Amgen's strategies to defend sales of its originator product and its successful transition to a next-generation pipeline.
Amgen's (AMGN) Xgeva (denosumab) is a $2.2 billion global blockbuster drug, and this EMA marketing authorization is a key factor in maintaining its market dominance within the European Union (EU). It has demonstrated superior efficacy in preventing skeletal-related events (SREs) compared to Zometa (zoledronic acid) in Phase 3 clinical trials, helping to maintain its prescription advantage. However, the recent patent expiration and the launch of biosimilars such as Wyost from Sandoz pose a significant challenge to its long-term sales. Its subcutaneous injection administration method, which offers greater convenience, has rapidly replaced existing intravenous treatments and remains a strong clinical incentive for researchers and healthcare professionals. In the short term, rapid listing on national health insurance programs in each European member state is expected to maximize sales, while in the long term, Amgen's ability to maintain profitability through a diversified portfolio will be put to the test as it faces pressure to lower the price of its originator product.
Source: EMA (ema)